13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
82 檔
19.1%
At the close of Q3 2025, Silverarc Capital Management, LLC disclosed equity holdings valued at approximately $962.2M, spread across 82 reported holdings.
In Q3 2025, Silverarc Capital Management, LLC displayed an active expansion posture, initiating 44 new positions and adding to 21 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 6.18% | -1.09% | — | |
| 2 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 5.04% | +0.87% | -7.68% | |
| 3 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 4.96% | — | +106.01% | |
| 4 | NUVL | Nuvalent Inc-a | Stock-Other | 4.34% | -3.71% | EXIT | |
| 5 | URGN | UroGen Pharma Ltd. | Stock-Other | 4.24% | +2.22% | -22.01% | |
| 6 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.12% | — | -9.83% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 4.01% | -0.22% | -17.03% | |
| 8 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.58% | -1.66% | +604.51% | |
| 9 | QURE | uniQure N.V. | Stock-Other | 3.58% | +0.50% | NEW | |
| 10 | CGON | Cg Oncology Inc | Stock-Other | 3.47% | -1.15% | EXIT | |
| 11 | ✓ | United Therapeutics CORP Del | Stock-Other | 3.39% | — | — | |
| 12 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.15% | -0.59% | +8.22% | |
| 13 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.85% | — | +112.52% | |
| 14 | GUTS | Fractyl Health Inc | Stock-Other | 2.27% | +0.06% | +5132.24% | |
| 15 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.24% | -5.91% | EXIT | |
| 16 | KOD | Kodiak Sciences Inc | Stock-Other | 2.21% | -1.65% | +149.04% | |
| 17 | ✓ | Ultragenyx Pharmaceutical In | Stock-Other | 2.14% | — | — | |
| 18 | GOSS | Gossamer Bio Inc | Stock-Other | 1.69% | — | -7.14% | |
| 19 | COGT | Cogent Biosciences Inc | Stock-Other | 1.58% | -0.01% | — | |
| 20 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.56% | -0.48% | EXIT | |
| 21 | PCVX | Vaxcyte Inc | Stock-Other | 1.53% | +0.02% | +9.22% | |
| 22 | BIIB | Biogen Inc | Stock-Healthcare | 1.52% | +0.13% | — | |
| 23 | ASND | Ascendis Pharma A/S | Stock-Other | 1.44% | -2.91% | EXIT | |
| 24 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.34% | -0.46% | EXIT | |
| 25 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.28% | — | — | |
| 26 | VSTM | Verastem Inc | Stock-Other | 1.24% | — | — | |
| 27 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.24% | +0.96% | NEW | |
| 28 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.23% | — | — | |
| 29 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.22% | -0.58% | EXIT | |
| 30 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.17% | -1.70% | EXIT | |
| 31 | VCYT | Veracyte Inc | Stock-Other | 1.09% | +1.35% | -47.43% | |
| 32 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.96% | +0.64% | +15.07% | |
| 33 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.82% | — | — | |
| 34 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.76% | — | — | |
| 35 | ALKS | Alkermes plc | Stock-Healthcare | 0.73% | -1.04% | — | |
| 36 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.73% | +0.69% | +9.12% | |
| 37 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.71% | — | — | |
| 38 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.71% | +0.09% | +8.37% | |
| 39 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 40 | ✓ | Cogent Biosciences Inc | Stock-Other | 0.70% | — | — | |
| 41 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.69% | -0.57% | — | |
| 42 | ✓ | Compugen LTD | Stock-Other | 0.66% | -0.01% | +9.14% | |
| 43 | PHVS | Pharvaris N.V. | Stock-Other | 0.62% | — | — | |
| 44 | CELC | Celcuity Inc | Stock-Other | 0.59% | +1.28% | — | |
| 45 | CERS | Cerus CORP | Stock-Other | 0.58% | +0.46% | +9.14% | |
| 46 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.57% | +0.96% | — | |
| 47 | TELA | Tela Bio Inc | Stock-Other | 0.56% | +0.03% | +0.11% | |
| 48 | AARD | Aardvark Therapeutics Inc | Stock-Other | 0.55% | -0.01% | EXIT | |
| 49 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.53% | — | — | |
| 50 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.52% | +0.17% | +9.10% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +5.9% | — | Add |
| 2 | QURE | uniQure N.V. | +3.1% | +124.62% | Add |
| 3 | DNTH | Dianthus Therapeutics Inc | +2.9% | +604.51% | Add |
| 4 | RNAGBP | Avidity Biosciences Inc | +2.5% | +106.01% | Add |
| 5 | GUTS | Fractyl Health Inc | +2.2% | +5132.24% | Add |
| 6 | KOD | Kodiak Sciences Inc | +2% | +149.04% | Add |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | +1.4% | -7.68% | Add |
| 8 | URGN | UroGen Pharma Ltd. | +1.1% | -22.01% | Add |
| 9 | CMPX | Compass Therapeutics Inc | +1% | +126.76% | Add |
| 10 | ORIC | Oric Pharmaceuticals Inc | +0.8% | +8.22% | Trim |
| 11 | CLDX | Celldex Therapeutics Inc | +0.5% | +75.83% | Add |
| 12 | AARD | Aardvark Therapeutics Inc | +0.4% | +7.01% | Add |
| 13 | CCCC | C4 Therapeutics Inc | +0.3% | — | Add |
| 14 | GOSS | Gossamer Bio Inc | +0.3% | -7.14% | Trim |
| 15 | SION | Sionna Therapeutics Inc | +0.2% | -41.51% | Trim |
| 16 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.1% | +17.05% | Add |
| 17 | TRVI | Trevi Therapeutics Inc | +0.1% | +9.12% | Add |
| 18 | RCKTW | Rocket Pharmaceuticals In-27 | — | — | Unchanged |
| 19 | RADX | Radiopharm Theranostics LTD | 0% | — | Unchanged |
| 20 | ALKS | Alkermes plc | -0.1% | — | Add |
| 21 | CERS | Cerus CORP | -0.1% | +9.14% | Add |
| 22 | TELA | Tela Bio Inc | -0.1% | +0.11% | Add |
| 23 | BNTC | Benitec Biopharma Inc | -0.2% | +9.10% | Add |
| 24 | ✓ | Modular Med Inc | -0.2% | -9.97% | Trim |
| 25 | ✓ | Compugen LTD | -0.2% | +9.14% | Add |
| 26 | DCTH | Delcath Systems Inc | -0.2% | +97.41% | Add |
| 27 | 260 | Centessa Pharmaceuticals-adr | -0.2% | +2724.76% | Trim |
| 28 | MLYS | Mineralys Therapeutics Inc | -0.7% | -30.61% | Trim |
| 29 | PRAX | Praxis Precision Medicines I | -0.9% | +412.10% | Trim |
| 30 | ASND | Ascendis Pharma A/S | -1% | -38.13% | Trim |
| 31 | INSM | Insmed Inc | -1% | -17.03% | Trim |
| 32 | ELUT | Elutia Inc | -1% | +3.23% | Add |
| 33 | ERAS | Erasca Inc | -1.7% | -46.76% | Trim |
| 34 | 4XC1 | Kalvista Pharmaceuticals Inc | -1.8% | -25.59% | Trim |
| 35 | AKRO | Akero Therapeutics Inc | -1.8% | -9.83% | Trim |
| 36 | NUVL | Nuvalent Inc-a | -2% | +58.03% | Trim |
| 37 | SNDX | Syndax Pharmaceuticals Inc | -2.3% | +15.07% | Trim |
| 38 | VCYT | Veracyte Inc | -2.8% | -47.43% | Trim |
| 39 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 40 | ✓ | Merus N V | — | EXIT | Sold out |
| 41 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 42 | ✓ | United Therapeutics CORP Del | — | NEW | New buy |
| 43 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 44 | ✓ | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 45 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 46 | IRON | Disc Medicine Inc | — | EXIT | Sold out |
| 47 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 48 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 49 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 50 | BIIB | Biogen Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 82 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, RYTM, RNAGBP) accounted for 19.1% of total reported equity market value during Q3 2025.
Top New Position Initiated
CGON
市值: $25.7M
Top Position Liquidated / Trimmed
VRNA
前期市值: $34.7M
During Q3 2025, Silverarc Capital Management, LLC's top holdings by market value included ABVX (6.2%)、RYTM (5.0%)、RNAGBP (5.0%). The largest single position, ABVX, represented 6.2% of total portfolio value.
In Q3 2025, Silverarc Capital Management, LLC made 111 total portfolio adjustments, initiating 44 new buys, adding to 21 positions, trimming 15 holdings, and fully liquidating 31 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.